VC004

VC004 (proposed generic name: Eratrectinib) is a Class 1 small-molecule oral anti-tumor targeted drug independently developed by Jiangsu Vcare. As a new generation of TRK inhibitor, VC004 not only demonstrates superior efficacy to first-generation drugs targeting the same molecule in clinical practice but also addresses the secondary drug resistance caused by first-generation drugs. VC004 is expected to bring longer survival benefits and better quality of life to patients. Studies have shown that VC004 has the following differentiated advantages: It features a unique second-generation anti-resistance mechanism. Based on in vitro kinase assay results, compared with first-generation drugs targeting the same molecule, VC004 not only has comparable targeted inhibitory activity against wild-type TRK but also possesses nM-level anti-resistance ability against first-generation drugs; VC004 shows significant clinical efficacy in both treatment-naive and previously treated patients. Based on the results of the single-arm pivotal Phase Ⅱ clinical study, VC004 shows a higher ORR than first-generation drugs, demonstrating significant clinical benefits in patients previously treated with TRK-TKIs; VC004 exhibits favorable clinical safety, with a significantly lower incidence of treatment-related serious adverse events (TRSAEs) than drugs targeting the same molecule, and no fatal TRSAEs reported. Currently, all first-generation drugs targeting the same molecule in the Chinese market are imported original research drugs and have not yet been fully approved for marketing, and there are no approved second-generation drugs of the same target. Clinical demand is far from being fully met. In China, VC004 has adopted a single-arm Phase Ⅱ study as its pivotal clinical trial, and its NDA has been accepted and is undergoing priority review. In the US, its IND application has been approved by FDA, and it is expected to become a world-leading new generation of TRK inhibitor.

Sumecigrel

Sumecigrel is an anti‑platelet aggregation agent and a new‑generation oral P2Y12 receptor antagonist. It is under clinical development for the treatment and prevention of atherothrombotic events, including acute coronary syndrome (ACS) secondary to coronary heart disease, ischemic stroke and peripheral arterial disease.Designed to address the black‑box warning regarding clopidogrel resistance, Sumecigrel retains the identical active metabolite as clopidogrel. It seeks to achieve a better balance between therapeutic benefits and bleeding risks, the well‑recognized “double‑edged sword” of anti‑platelet agents.A comprehensive clinical development program has been conducted across healthy volunteers and patient populations, covering multiple Phase I, Phase II, PK‑PD bridging and Phase III studies. Compared with existing agents, Sumecigrel features the following core advantages: ‑ It ameliorates and counteracts the influence of CYP2C19 genetic polymorphism on clopidogrel, delivering more consistent efficacy; ‑ It shows equivalent efficacy to clopidogrel in CYP2C19 normal metabolizers with manageable bleeding risk; ‑ It avoids dose loss resulting from the ineffective first‑step metabolism of clopidogrel, supporting a lower therapeutic dose, faster onset of action and reduced adverse drug‑drug interactions (DDIs); ‑ Its metabolite profile is fully encompassed by that of clopidogrel. No parent‑drug‑related unique metabolites have been detected, which reinforces its reliability for clinical application.Currently, the NDA for Sumecigrel has been accepted in China, and NDA submission preparation is in progress in the United States.

VC005

VC005 is a novel, potent, and highly selective second-generation JAK1 inhibitor independently developed by Jiangsu Vcare. It is used clinically to treat diseases in the fields of inflammation and autoimmunity. It has been developed into two dosage forms, oral tablets and topical gel. VC005 potently inhibits JAK1 and moderately inhibits TYK2 in a synergistic manner, while markedly reducing inhibition against JAK2 and JAK3. Clinically, it is expected to mitigate safety concerns arising from excessive JAK2 and JAK3 inhibition. Currently, VC005 has demonstrated significant efficacy and differentiated safety advantages in multiple clinical studies. VC005 Tablets have been developed for multiple indications, including moderate-to-severe atopic dermatitis (Phase III clinical trial met primary endpoints), ankylosing spondylitis (Phase III clinical trial completed patient enrollment), vitiligo (Phase II clinical trial met primary endpoints), rheumatoid arthritis (completed Phase Ib clinical trial), and inflammatory bowel disease (completed Phase I clinical trial). The VC005 topical gel is under development for mild-to-moderate atopic dermatitis (Phase III clinical trial ongoing patient enrollment).